Cached score snapshot

US.RVTY · Revvity

110分制 61.5/110;5D動能v2 4/50;排序分 65.5/160

Ranking score 65.5/160
Main score 61.5/110
5D momentum v2 4/50
Rank #107
Setup grade F 29.5

Score breakdown

觀望

Elevated twelvedata

Score and price trend

F 29.5 Elevated risk

Main score, 5D momentum v2, close price, and improving or exit-review turn signals are plotted from archived daily snapshots.

Move the mouse over the chart lines to inspect readings.

0 40 80 110 Score 06-12 07-28 09-09 09-30 10-20 $91.55$130.06$168.56 Price Projection date
Historical projection
Model Median P25/P75 歷史相似情境上漲比例 Down5 Actual / compare
Rolling DOE best · score 2.226 · anchors 120 +1.19% -0.90% / +2.74% 61.3% 5% Actual -2.18% · vs median -3.37% · inside 25-75 band
30D observation +10.07% -1.44% / +21.85% 68.8% 13.8% Actual outcome pending · 1 / 30 bars observed
Historical projection 10D n=160 +0.74% -0.84% / +2.47% 60.6% 5% Actual outcome pending · 1 / 10 bars observed

歷史情境統計基於已存檔相似 setup;圖中投影中位線為統計中位數的線性插值展示,並非價格路徑預測或買賣建議。

2026-06-12 → 2026-10-20 · 119 archived points · 2 Improving turn signal · 7 Deteriorating signal

Summary

score_with_momentum_v2 = main score + 5D momentum v2

Ranking score 65.5
Display grade 觀望
Model version cursor_18_27_news_v2_160
Main score 61.5/110 (觀望)
5D momentum v2 4/50 (弱)
Score with momentum v2 65.5/160 (低排序)
Risk level Elevated

Audit trace

Full calculation detail

Calculation detail · 8 sections

Market inputs

Bar count 60
ma20 123.6515
ma50 116.6782
close 127.08
prevClose 130.22
avgVolume20 1553342
volumeRatio 0.96
changePercent -2.41

Metrics snapshot

close 127.08
volume 1491046
changePercent -2.41

110-point main rating

基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10

Main score 61.5/110
Main rating 觀望
5D momentum v2 4/50
Score with momentum v2 65.5/160
Formula score_with_momentum_v2 = main_score + momentum_5d_v2_score

基本面 — 2.4/5 · 較差

Dimension score 2.4/5
Dimension grade 較差

Sub-items

pbPoints 0.5
pePoints 0.2
epsPoints 0
roePoints 0
debtPoints 0.5
marginPoints 0
turnoverUsdM 189.4821
volumePoints 0.5
revenuePoints 0
dividendPoints 0.3
marketCapPoints 0.4

資金流 — 13.2/20 · 一般

Dimension score 13.2/20
Dimension grade 一般

Sub-items

cmfPoints 3.2
mfiPoints 3.2
obvPoints 0.8
vwapPoints 4

institutional

score 2

details

source optional-neutral

warning

code INSTITUTIONAL_DATA_OPTIONAL
symbol US.RVTY
message Institutional ownership is unavailable; neutral 2/4 money-flow treatment used.
optional true
holderCount n/a
holderPoints 2
top10ShareRatio n/a
concentrationPenalty 0
institutionPoints 2

市場環境 — 11/15 · 良好

Dimension score 11/15
Dimension grade 良好

Sub-items

vix

score 2.4

details

source twelvedata+fred
vixClose 15.3

trend

score 3.4

details

qqq

ma20 717.385
ma50 711.3218
name QQQ
close 718.36
points 2

spy

ma20 768.6995
ma50 757.5966
name SPY
close 765.96
points 1.4
source twelvedata+fred
atrPct 3.2994
atrPoints 2
cciPoints 3.2
vixPoints 2.4
marketTrendPoints 3.4

催化劑 — 2/20 · 較差

Dimension score 2/20
Dimension grade 較差

Sub-items

catalyst

score 2

details

source finnhub_news_keyword_model
articleCount 5
catalystCount 0
catalystPoints 2

風險管理 — 6.3/10 · 一般

Dimension score 6.3/10
Dimension grade 一般

Sub-items

position

score 1.1

details

atrPct 3.2994
turnoverUsdM 189.4821
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.RVTY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 118.6942

strength_details

ma_score 1.5
atr_score 1
rsi_score 0.5
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 6.6
take_profit_price 133.7886
target_multiplier 1.6
technical_strength 1.5
take_profit_percent 5.3
positionPoints 1.1
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 6.5988
diversificationPoints 2

技術信號 — 20.6/30 · 一般

Dimension score 20.6/30
Dimension grade 一般

Sub-items

bbPoints 3
adxPoints 3
sarPoints 1.2
vcpPoints 2.7
macdPoints 4

vcpPayload

vcp_pass false
vcp_score 2.7
vcp_reason 波幅收縮(20.1%→9.1%);跌縮量(近10日3日);站上MA50;升放量(近10日2日);Ready=Y;Confirm=N

vcp_metrics

up_days 4
vol_ref 1638203.3333
down_days 5
vcp_ready true
above_ma50 true
avg_vol_10 1698800
avg_vol_20 1541480
avg_vol_30 1638203.3333
range_pct_10 0.0914
range_pct_20 0.1599
range_pct_30 0.2008
up_expand_ok true
lookback_used 59
near_20d_high true
contraction_ok true
down_shrink_ok true
up_expand_days 2
breakout_20d_ok false
vol_ratio_10_30 1.037
dist_to_20d_high 0.0445
down_shrink_days 3
breakout_level_20d 133
vcp_breakout_confirm false
contraction_ratio_10_30 0.4553
vcp_name_en Volatility Contraction Pattern
vcp_name_zh 波動收縮形態
vol_contraction true
kdjAdxPoints 0.5
rsiKdjPoints 2.4
volumeWeight 2
maCrossPoints 1.6
shortRsiPoints 0.4
shortMacdPoints 0.4
volConfirmPoints 0.6
volumePointsTechnical 0.8

情緒分析 — 6/10 · 一般

Dimension score 6/10
Dimension grade 一般

Sub-items

sentiment

score 6

details

source finnhub_news_keyword_model
articleCount 5
negativeHits 0
positiveHits 3
sentimentScoreRaw 1.4

sentimentData

raw {"id":141394957,"url":"https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...","category":"company","datetime":1788401656,"headline":"Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"}, {"id":141376585,"url":"https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...","category":"company","datetime":1788350787,"headline":"Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"}, {"id":141374543,"url":"https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489","image":"","source":"Fintel","related":"RVTY","summary":"","category":"company","datetime":1788331013,"headline":"RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"}, {"id":141370258,"url":"https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).","category":"company","datetime":1788282002,"headline":"What Makes Revvity (RVTY) a New Buy Stock"}, {"id":141202718,"url":"https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Diagnostics surged 11% organically as AI-driven demand accelerated.","category":"company","datetime":1786468489,"headline":"Revvity (RVTY) Q2 2026 Earnings Call Transcript"}
raw_source {"id":141950366,"url":"https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro","category":"company","datetime":1788878940,"headline":"Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"}, {"id":141425678,"url":"https://finnhub.io/api/news?id=f21a96053f253b59f417bd859feef95f766270d2e42bafa9937419d4bfaae0dc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.","category":"company","datetime":1788526140,"headline":"Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?"}, {"id":141420277,"url":"https://finnhub.io/api/news?id=8dff4283f6da452e92865d7101fd6ffa7f2bdc63d99febe33fac804fc18f8255","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher","category":"company","datetime":1788518880,"headline":"Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share"}, {"id":141449917,"url":"https://finnhub.io/api/news?id=2f5b6dbf3c6e63d29e248fc2bc5f667c787cd9f592de5860faa835e287e2cc01","image":"","source":"Benzinga","related":"RVTY","summary":"Keybanc analyst Paul Knight maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.","category":"company","datetime":1788513490,"headline":"Keybanc Maintains Overweight on Revvity, Raises Price Target to $165"}, {"id":141394957,"url":"https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...","category":"company","datetime":1788401656,"headline":"Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"}, {"id":141376585,"url":"https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...","category":"company","datetime":1788350787,"headline":"Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"}, {"id":141374543,"url":"https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489","image":"","source":"Fintel","related":"RVTY","summary":"","category":"company","datetime":1788331013,"headline":"RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"}, {"id":141373643,"url":"https://finnhub.io/api/news?id=586a7b0273e63c068b81acc8775f2c6ac9290074de64940276220f0e54d8f76b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.","category":"company","datetime":1788294620,"headline":"3 Hyped Up Stocks We Find Risky"}, {"id":141370258,"url":"https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).","category":"company","datetime":1788282002,"headline":"What Makes Revvity (RVTY) a New Buy Stock"}, {"id":141370259,"url":"https://finnhub.io/api/news?id=b4010c5290b28cfc54157cb45359ef75b9687f7cc7d4fb5bcd195348a5cc80a2","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo","category":"company","datetime":1788280978,"headline":"Revvity Faces Growth Challenges Amid Rising Competition, RBC Says"}, {"id":141370883,"url":"https://finnhub.io/api/news?id=da5596eb573a2739f70a4762282fc12f50cb2181b295291669cc4c0452c29761","image":"","source":"Benzinga","related":"RVTY","summary":"RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.","category":"company","datetime":1788249814,"headline":"RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135"}, {"id":141361171,"url":"https://finnhub.io/api/news?id=40e9f3152f995605f71edc54cd5e8da04b68760f2b599ba43b23754aa3a6049b","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"As UnitedHealth Group has outperformed relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects.","category":"company","datetime":1788072487,"headline":"How Is UnitedHealth Group's Stock Performance Compared to Other Healthcare Plan Stocks?"}, {"id":141365522,"url":"https://finnhub.io/api/news?id=ee488ce9869916a3010f25f71ecd7d44f2eb7e982a65bdbcd691644f069d6b25","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Investors need to pay close attention to RVTY stock based on the movements in the options market lately.","category":"company","datetime":1787589000,"headline":"Is the Options Market Predicting a Spike in Revvity Stock?"}, {"id":141365523,"url":"https://finnhub.io/api/news?id=eb1cf6f63665ff456ed353f202bb56f9038280ac16ecae9524ce05ca57689b3e","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.","category":"company","datetime":1787585403,"headline":"Revvity Stock: Is Wall Street Bullish or Bearish?"}, {"id":141263724,"url":"https://finnhub.io/api/news?id=79817c6765abca477c158dde61718bc04fe3d602b4fecbff929b0a7fcd1bb05a","image":"https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp","source":"ChartMill","related":"RVTY","summary":"Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.","category":"company","datetime":1787252701,"headline":"Exploring the top movers within the S&P500 index during today's session."}, {"id":141230562,"url":"https://finnhub.io/api/news?id=4d092ebe3aa6f83822c04a961bb022d30ba76830344f6c5fdbe0e95de91c9b2a","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1786857318,"headline":"Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside"}, {"id":141218677,"url":"https://finnhub.io/api/news?id=652224e6eaeca65523b7fcc05076da4b572b7f65213dd09624d1398b823f11df","image":"","source":"SeekingAlpha","related":"RVTY","summary":"","category":"company","datetime":1786721166,"headline":"Danaher: 2027 Growth Reacceleration Should Drive Upside"}, {"id":141206709,"url":"https://finnhub.io/api/news?id=abf15460060e9d68def7ae24c3778a414925e71cb70a7b8f3956a47e4e500adc","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.","category":"company","datetime":1786629600,"headline":"Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs"}, {"id":141202717,"url":"https://finnhub.io/api/news?id=e2a2e352b10892b67e53ab7554bbeb3ba8baff2bbefdfaba1a2267691b1082dd","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to \"tangible signs of a more constructive spending environmen","category":"company","datetime":1786587660,"headline":"The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call"}, {"id":141202718,"url":"https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Diagnostics surged 11% organically as AI-driven demand accelerated.","category":"company","datetime":1786468489,"headline":"Revvity (RVTY) Q2 2026 Earnings Call Transcript"}, {"id":141202719,"url":"https://finnhub.io/api/news?id=c4fbd63bd68321a1fd0751f6671df4d112f0dbc162a5bed08991df064ba072e3","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:","category":"company","datetime":1786449600,"headline":"Revvity to Present at Upcoming Investor Conferences"}, {"id":141174464,"url":"https://finnhub.io/api/news?id=63dd3feb8ba49e1ae84ce6a141b45b7a3b89f86583deb193b3dea0bea2fb5247","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.","category":"company","datetime":1786363200,"headline":"Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing"}, {"id":141173746,"url":"https://finnhub.io/api/news?id=40b71ceb7b13d365c949f86e7e49081f3457d6ee7e752ab19caba47ee97b41d8","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.","category":"company","datetime":1786360642,"headline":"1 Profitable Stock on Our Buy List and 2 We Find Risky"}, {"id":141164551,"url":"https://finnhub.io/api/news?id=28240c7696bd84e8c1650ca65c32607de843b27341b0f3371fb567d0795f9fd1","image":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","source":"Yahoo","related":"RVTY","summary":"Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows","category":"company","datetime":1786248230,"headline":"Revvity Q2 Earnings Call Highlights"}
data_source finnhub_news_keyword_model
article_count 5
negative_hits 0
positive_hits 3
recomputed_at_score true
sentiment_score_raw 1.4
source_article_count 24
discarded_article_count 19
sentimentPoints 6

Dimension contribution

Dimension Raw Max Norm % Contrib
基本面 2.4 5/110 48% 2.4
資金流 13.2 20/110 66% 13.2
市場環境 11 15/110 73.33% 11
催化劑 2 20/110 10% 2
風險管理 6.3 10/110 63% 6.3
技術信號 20.6 30/110 68.67% 20.6
情緒分析 6 10/110 60% 6

5D momentum v2 breakdown

Cursor_18.25 5D momentum v2 0-50

5D momentum v2 4/50
ret_5d -0.0124
max_score 50
max_total 50
raw_total 4
vcp_bonus 0
vol_ratio 0.9673
ret_points 0
vol_points 0
range_ratio 0.7313
volat_points 0
day_range_pct 0.0209
model_version cursor_18_27_news_v2_160
available_bars 30
breakout_points 0
partial_history false
pullback_points 4
breakout_vol_bonus 0
first_breakout_20d false
return_window_days 5
first_breakout_bonus 0
breakout_quality_points 0

Risk management

level Elevated
reason risk management score >= 5/10

position

score 1.1

details

atrPct 3.2994
turnoverUsdM 189.4821
liquidityPoints 0.4
volatilityPoints 0.7
rrPoints 1.4

stopLevels

symbol US.RVTY
rr_range 1:1.0-1:2.5
risk_profile 中等
stop_loss_price 118.6942

strength_details

ma_score 1.5
atr_score 1
rsi_score 0.5
macd_score 3
volume_score 1
market_adjustment 1
risk_reward_ratio 1
stop_loss_percent 6.6
take_profit_price 133.7886
target_multiplier 1.6
technical_strength 1.5
take_profit_percent 5.3
positionPoints 1.1
stopLossPoints 1.8

diversification

score 2

details

method sector concentration proxy; no portfolio holdings used
sector Health Care
concentratedSectorPenalty 0
riskRewardRatio 1.2
stopLossPercent 6.5988
diversificationPoints 2

Calculation audit log

基本面分析總分: 2.4/5分
資金流分析總分: 13.2/20分
市場環境分析總分: 11/15分
催化劑分析: 2/20分
風險管理總分: 6.3/10分
技術信號分析總分: 20.6/30分
情緒分析: 6/10分
共振率(僅顯示不加分): 0%

Technical indicators

adx
value 85.71
atr
atr 4.1929
rule ATR / current price; lower volatility scores higher
score 4
atr_pct 3.3
cci
rule Cursor_18.24 CCI bands
level 適中偏強
score 8
value 64.28
cmf
rule Cursor_18.24 CMF bands
level 資金流入
score 8
value 0.2946
kdj
d 79.59
j 43.34
k 67.5
rule Cursor_18.24 K/D cross
score 0
signal 死叉
mfi
rule Cursor_18.24 MFI bands
level 入貨中
score 8
value 68.98
obv
rule Cursor_18.24 recent_slope vs previous_slope
score 2
trend 資金流出
value 10418854
recentSlope -555804.6
previousSlope 336160
rsi
value 71.65
sar
rule Cursor_18.24 Parabolic SAR
score 4
trend 下降
value 133
position SAR喺價上
distancePct 4.66
previousTrend 上升
ma50
value 116.6782
macd
macd 4.2093
trend 強烈看漲
signal 4.1072
histogram 0.1021
vwap
rule Cursor_18.24 VWAP 20D consecutive close
score 10
value 124.1891
position 連續5日>VWAP
consecutiveAbove 24
volume
rule Cursor_18.24 volume ratio
level 無力
ratio 0.96
score 4
avgVolume 1553342
currentVolume 1491046
derived
ma20 123.6515
ma50 116.6782
prevClose 130.22
avgVolume10 1697365
avgVolume20 1553342
changePercent -2.41
avgVolumeForScore 1553342
ma_cross
ma20 123.6515
ma50 116.6782
rule Cursor_18.24 MA20/MA50 cross
cross 多頭
score 4
prevMa20 123.0985
prevMa50 116.397
spreadPct 5.98
isVolumeBreakout false
bollinger
lower 112.5495
upper 134.7535
position 上半部
rsi_short
value 41.75
macd_short
macd 0
trend 中性
signal 0
histogram 0
volume_ratio
ratio 0.96

Raw calculation JSON

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.2994176377176956,
        "turnoverUsdM": 189.482128662092,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.RVTY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 118.6942,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6.6,
      "take_profit_price": 133.7886,
      "target_multiplier": 1.6,
      "technical_strength": 1.5,
      "take_profit_percent": 5.3
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.598835275435391,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65.5,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.5,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 123.6515,
    "ma50": 116.6782,
    "close": 127.08,
    "prevClose": 130.22,
    "avgVolume20": 1553342,
    "volumeRatio": 0.96,
    "changePercent": -2.41
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": -0.012357177275200026,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 0.9672820925344474,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.7313196523165912,
      "volat_points": 0,
      "day_range_pct": 0.02085292696171022,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 4,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65.5,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 48,
        "contribution": 2.4
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 11,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 73.33,
        "contribution": 11
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 20.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 68.67,
        "contribution": 20.6
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 61.5,
    "details": [
      "基本面分析總分: 2.4/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 11/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 20.6/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.4,
      "資金流": 13.2,
      "市場環境": 11,
      "情緒分析": 6,
      "技術信號": 20.6,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 189.482128662092,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.4
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 3.2,
          "obvPoints": 0.8,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.RVTY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.3
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 717.3850005500001,
                "ma50": 711.3217994399997,
                "name": "QQQ",
                "close": 718.35999,
                "points": 2
              },
              "spy": {
                "ma20": 768.6994929500001,
                "ma50": 757.5966012200001,
                "name": "SPY",
                "close": 765.96002,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.2994176377176956,
          "atrPoints": 2,
          "cciPoints": 3.2,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 5,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 1.4
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141394957,
                "url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
                "category": "company",
                "datetime": 1788401656,
                "headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
              },
              {
                "id": 141376585,
                "url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
                "category": "company",
                "datetime": 1788350787,
                "headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
              },
              {
                "id": 141374543,
                "url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
                "image": "",
                "source": "Fintel",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788331013,
                "headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
              },
              {
                "id": 141370258,
                "url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1788282002,
                "headline": "What Makes Revvity (RVTY) a New Buy Stock"
              },
              {
                "id": 141202718,
                "url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
                "category": "company",
                "datetime": 1786468489,
                "headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 141950366,
                "url": "https://finnhub.io/api/news?id=9ffbefa46ae6a3e4ca32751051e8d41fdf4e5c7ea74772461a6e2e856ea0ded6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The \"Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031\" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro",
                "category": "company",
                "datetime": 1788878940,
                "headline": "Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others"
              },
              {
                "id": 141425678,
                "url": "https://finnhub.io/api/news?id=f21a96053f253b59f417bd859feef95f766270d2e42bafa9937419d4bfaae0dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.",
                "category": "company",
                "datetime": 1788526140,
                "headline": "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141420277,
                "url": "https://finnhub.io/api/news?id=8dff4283f6da452e92865d7101fd6ffa7f2bdc63d99febe33fac804fc18f8255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher",
                "category": "company",
                "datetime": 1788518880,
                "headline": "Global Multiplex Assays Market 2026 Edition -  Consumables Dominate Multiplex Assays with 68% Market Share"
              },
              {
                "id": 141449917,
                "url": "https://finnhub.io/api/news?id=2f5b6dbf3c6e63d29e248fc2bc5f667c787cd9f592de5860faa835e287e2cc01",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "Keybanc  analyst Paul Knight   maintains Revvity (NYSE:RVTY) with a Overweight and raises the price target from $125 to $165.",
                "category": "company",
                "datetime": 1788513490,
                "headline": "Keybanc Maintains Overweight on Revvity, Raises Price Target to $165"
              },
              {
                "id": 141394957,
                "url": "https://finnhub.io/api/news?id=c8b12fe4ed72ebc17bbb88c0ab2ddd6a474f4769bdf66b17e58abdee92cf8f1d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based multiples point to a richer price. Revvity’s 57.5% 1 year return sets a high bar for new buyers, who now need the fundamentals to justify a much higher share price base. The key support for the current valuation can come from the company’s ability to convert...",
                "category": "company",
                "datetime": 1788401656,
                "headline": "Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings"
              },
              {
                "id": 141376585,
                "url": "https://finnhub.io/api/news?id=323914a6aab244c46436fbc5e705d5ab656e998a732346d572925b8e2cabe6fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) is back in focus after a recent Zacks upgrade to Rank #2, which reflects improved earnings expectations even as questions remain about growth momentum and rising competitive pressure. Over the past year Revvity’s share price return has been strong, with a 30 day share price return of 12.5%, a 90 day share price return of 25.25% and a year to date share price return of 28.98%, while the 1 year total shareholder return is 44.46%. This suggests that positive momentum has been...",
                "category": "company",
                "datetime": 1788350787,
                "headline": "Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade"
              },
              {
                "id": 141374543,
                "url": "https://finnhub.io/api/news?id=3c3b31f83fc72e07cc004c2544df885b3ea92baad1ce785e6334735ff53c1489",
                "image": "",
                "source": "Fintel",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1788331013,
                "headline": "RBC Capital Initiates Coverage of Revvity (RVTY) with Sector Perform Recommendation"
              },
              {
                "id": 141373643,
                "url": "https://finnhub.io/api/news?id=586a7b0273e63c068b81acc8775f2c6ac9290074de64940276220f0e54d8f76b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.",
                "category": "company",
                "datetime": 1788294620,
                "headline": "3 Hyped Up  Stocks We Find Risky"
              },
              {
                "id": 141370258,
                "url": "https://finnhub.io/api/news?id=6545bb751ae949e0c7ab96f599e32d8cc54b53cc4e6e0674e3f677f9ceef0bf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).",
                "category": "company",
                "datetime": 1788282002,
                "headline": "What Makes Revvity (RVTY) a New Buy Stock"
              },
              {
                "id": 141370259,
                "url": "https://finnhub.io/api/news?id=b4010c5290b28cfc54157cb45359ef75b9687f7cc7d4fb5bcd195348a5cc80a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity's (RVTY) strong portfolio faces slowing growth and rising competition, raising questions abo",
                "category": "company",
                "datetime": 1788280978,
                "headline": "Revvity Faces Growth Challenges Amid Rising Competition, RBC Says"
              },
              {
                "id": 141370883,
                "url": "https://finnhub.io/api/news?id=da5596eb573a2739f70a4762282fc12f50cb2181b295291669cc4c0452c29761",
                "image": "",
                "source": "Benzinga",
                "related": "RVTY",
                "summary": "RBC Capital  analyst Dan Leonard   initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform rating and announces Price Target of $135.",
                "category": "company",
                "datetime": 1788249814,
                "headline": "RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135"
              },
              {
                "id": 141361171,
                "url": "https://finnhub.io/api/news?id=40e9f3152f995605f71edc54cd5e8da04b68760f2b599ba43b23754aa3a6049b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "As UnitedHealth Group has outperformed relative to its industry peers over the past year, Wall Street analysts remain bullish about the stock’s prospects.",
                "category": "company",
                "datetime": 1788072487,
                "headline": "How Is UnitedHealth Group's Stock Performance Compared to Other Healthcare Plan Stocks?"
              },
              {
                "id": 141365522,
                "url": "https://finnhub.io/api/news?id=ee488ce9869916a3010f25f71ecd7d44f2eb7e982a65bdbcd691644f069d6b25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Investors need to pay close attention to RVTY stock based on the movements in the options market lately.",
                "category": "company",
                "datetime": 1787589000,
                "headline": "Is the Options Market Predicting a Spike in Revvity Stock?"
              },
              {
                "id": 141365523,
                "url": "https://finnhub.io/api/news?id=eb1cf6f63665ff456ed353f202bb56f9038280ac16ecae9524ce05ca57689b3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1787585403,
                "headline": "Revvity Stock: Is Wall Street Bullish or Bearish?"
              },
              {
                "id": 141263724,
                "url": "https://finnhub.io/api/news?id=79817c6765abca477c158dde61718bc04fe3d602b4fecbff929b0a7fcd1bb05a",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "RVTY",
                "summary": "Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787252701,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141230562,
                "url": "https://finnhub.io/api/news?id=4d092ebe3aa6f83822c04a961bb022d30ba76830344f6c5fdbe0e95de91c9b2a",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1786857318,
                "headline": "Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside"
              },
              {
                "id": 141218677,
                "url": "https://finnhub.io/api/news?id=652224e6eaeca65523b7fcc05076da4b572b7f65213dd09624d1398b823f11df",
                "image": "",
                "source": "SeekingAlpha",
                "related": "RVTY",
                "summary": "",
                "category": "company",
                "datetime": 1786721166,
                "headline": "Danaher: 2027 Growth Reacceleration Should Drive Upside"
              },
              {
                "id": 141206709,
                "url": "https://finnhub.io/api/news?id=abf15460060e9d68def7ae24c3778a414925e71cb70a7b8f3956a47e4e500adc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.",
                "category": "company",
                "datetime": 1786629600,
                "headline": "Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs"
              },
              {
                "id": 141202717,
                "url": "https://finnhub.io/api/news?id=e2a2e352b10892b67e53ab7554bbeb3ba8baff2bbefdfaba1a2267691b1082dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity’s second quarter demonstrated year-over-year growth in both revenue and non-GAAP earnings, yet the market responded negatively, likely reflecting concerns about underlying segment dynamics and external factors. Management highlighted continued strength in its Diagnostics franchise, supported by robust organic growth and consistent performance in reproductive health and immunodiagnostics outside China. CEO Prahlad Singh pointed to \"tangible signs of a more constructive spending environmen",
                "category": "company",
                "datetime": 1786587660,
                "headline": "The Top 5 Analyst Questions From Revvity’s Q2 Earnings Call"
              },
              {
                "id": 141202718,
                "url": "https://finnhub.io/api/news?id=dc4b5e57db7b5cfc95b47aee78ff5769146561bed914b9ca8acce70d4081b2a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Diagnostics surged 11% organically as AI-driven demand accelerated.",
                "category": "company",
                "datetime": 1786468489,
                "headline": "Revvity (RVTY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141202719,
                "url": "https://finnhub.io/api/news?id=c4fbd63bd68321a1fd0751f6671df4d112f0dbc162a5bed08991df064ba072e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., August 11, 2026--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:",
                "category": "company",
                "datetime": 1786449600,
                "headline": "Revvity to Present at Upcoming Investor Conferences"
              },
              {
                "id": 141174464,
                "url": "https://finnhub.io/api/news?id=63dd3feb8ba49e1ae84ce6a141b45b7a3b89f86583deb193b3dea0bea2fb5247",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "WALTHAM, Mass., August 10, 2026--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows.",
                "category": "company",
                "datetime": 1786363200,
                "headline": "Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing"
              },
              {
                "id": 141173746,
                "url": "https://finnhub.io/api/news?id=40b71ceb7b13d365c949f86e7e49081f3457d6ee7e752ab19caba47ee97b41d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1786360642,
                "headline": "1 Profitable Stock on Our Buy List and 2 We Find Risky"
              },
              {
                "id": 141164551,
                "url": "https://finnhub.io/api/news?id=28240c7696bd84e8c1650ca65c32607de843b27341b0f3371fb567d0795f9fd1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "RVTY",
                "summary": "Revvity (NYSE:RVTY) reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows",
                "category": "company",
                "datetime": 1786248230,
                "headline": "Revvity Q2 Earnings Call Highlights"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 5,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.4,
            "source_article_count": 24,
            "discarded_article_count": 19
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.6,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(20.1%→9.1%);跌縮量(近10日3日);站上MA50;升放量(近10日2日);Ready=Y;Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 1638203.3333333333,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1698800,
              "avg_vol_20": 1541480,
              "avg_vol_30": 1638203.3333333333,
              "range_pct_10": 0.09143846252064117,
              "range_pct_20": 0.1598992735300712,
              "range_pct_30": 0.20081837896099497,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0369897102720258,
              "dist_to_20d_high": 0.04451126315789479,
              "down_shrink_days": 3,
              "breakout_level_20d": 133,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.45532915360501586
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.2994176377176956,
              "turnoverUsdM": 189.482128662092,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.RVTY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 118.6942,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6.6,
            "take_profit_price": 133.7886,
            "target_multiplier": 1.6,
            "technical_strength": 1.5,
            "take_profit_percent": 5.3
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.598835275435391,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 85.71,
    "atr": {
      "atr": 4.1929,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.3
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 64.28
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2946
    },
    "kdj": {
      "d": 79.59,
      "j": 43.34,
      "k": 67.5,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 68.98
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": 10418854,
      "recentSlope": -555804.6,
      "previousSlope": 336160
    },
    "rsi": 71.65,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 133,
      "position": "SAR喺價上",
      "distancePct": 4.66,
      "previousTrend": "上升"
    },
    "ma50": 116.6782,
    "macd": {
      "macd": 4.209307111240491,
      "trend": "強烈看漲",
      "signal": 4.107223083560831,
      "histogram": 0.10208402767965996
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 124.1891,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 24
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.96,
      "score": 4,
      "avgVolume": 1553342,
      "currentVolume": 1491046
    },
    "derived": {
      "ma20": 123.6515,
      "ma50": 116.6782,
      "prevClose": 130.22,
      "avgVolume10": 1697365,
      "avgVolume20": 1553342,
      "changePercent": -2.41,
      "avgVolumeForScore": 1553342
    },
    "ma_cross": {
      "ma20": 123.6515,
      "ma50": 116.6782,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 123.0985,
      "prevMa50": 116.397,
      "spreadPct": 5.98,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 112.5495,
      "upper": 134.7535,
      "position": "上半部"
    },
    "rsi_short": 41.75,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.96
    }
  }
}

Raw metrics JSON

{
  "close": 127.08,
  "volume": 1491046,
  "changePercent": -2.41
}

Scores are derived from cached daily market data using the Cursor_18.25 standard. Solorank.ai provides research support only and does not provide financial advice or buy/sell recommendations.